|
ARAMIS trial: Efficacy and safety phase 3 trial of ODM-201 in men with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC). |
|
|
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Curevac; Dendreon; Ipsen; Janssen Oncology; Novartis; Orion; Sanofi; Takeda |
Speakers' Bureau - Amgen; Astellas Pharma; Janssen Oncology; Sanofi |
Travel, Accommodations, Expenses - Amgen |
|
|
Consulting or Advisory Role - Astellas Pharma; Bayer; Dendreon; Ferring; Janssen; Millennium; Pfizer; Sanofi |
Research Funding - Carolina Urologic Research Center |
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Dendreon; Ferring; Janssen; Millennium; Pfizer; Sanofi |
|
|
Consulting or Advisory Role - Amgen; Astellas Pharma; Janssen-Cilag; Pfizer |
Research Funding - Amgen; Astellas Pharma; Janssen-Cilag; Medivation; Orion |
|
|
|
|
|
|
|
|
|
Stock and Other Ownership Interests - Bayer |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |